NeoRx Corp.

300 Elliot Avenue West, Suite 500
Seattle, WA 98119

USA

Phone: (206) 281-7001
Fax: (206) 286-2537
Web Site: http://www.neorx.com/

A. Company Profile

NeoRx (NASDAQ:NERX) is a cancer therapeutic development company with technologies for targeted delivery of therapeutic agents, including radiopharmaceuticals, directly to sites of cancer.

B. Products

Product Pipelines

1. Skeletal Targeted Radiotherapy (STR)

Skeletal Targeted Radiotherapy (STR) for use with high-dose chemotherapy and stem cell transplantation to treat patients with multiple myeloma and potentially other bone and bone-marrow related cancers, and bone metastases of primary carcinomas. 

The STR therapeutic agent is a bone-targeting molecule complexed with the radionuclide holmium-166. STR is designed to deliver radiation directly to cancers in the bone and bone marrow, with minimal toxicity to organs outside the bone. STR provides rapid, efficient uptake of radioactivity into the bone and marrow cavity, where the radionuclide exerts a direct therapeutic effect on myeloma cells and their precursors, plus a general marrow-ablative effect. 

2. Pretarget Lymphoma

Pretarget Lymphoma employs a fusion protein with the targeting specificity of the well-characterized and clinically successful anti-CD20 monoclonal antibody, to deliver the radionuclide yttrium-90. Treatment with Pretarget Lymphoma was usually well tolerated.

3. Pretarget Carcinoma

Pretarget Carcinoma uses a fusion protein with the specificity and avidity of the CC49 monoclonal antibody that binds the well-characterized TAG-72 antigen on adenocarcinomas (including many gastrointestinal, pancreatic, prostate, breast, ovary and other tumors). The regimen was generally safe and well tolerated, with high tumor uptake of the radiotherapeutic relative to other organs, and less bone marrow exposure than is typically seen with directly radiolabeled antibody targeting agents.